Myriad Genetics drug discovery, neurological, autoimmune/inflammation news

MYGN formed a subsidiary, Myriad Pharmaceuticals Inc., to screen for small molecule therapeutic candidates against drug targets discovered with MYGN's ProNet protein interaction technology. Myriad will validate the targets and perform preclinical testing on candidates before partnering them for clinical development. The subsidiary will concentrate initially on treatments for pain, angiogenesis, arthritis and other inflammatory disorders. ...